Onasemnogene abeparvovec for muscular atrophy, spinal

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Also followed for narrower conditions: Bulbo-Spinal Atrophy, X-Linked, Spinal Muscular Atrophies of Childhood

Why this status

  1. 11 Oct 2017: Trial registered, NCT03306277
  2. 24 Oct 2017: Trial started, NCT03306277
  3. 2 Apr 2018: Trial started, NCT03505099
  4. 23 Apr 2018: Trial registered, NCT03505099

The trials

NCT03306277: Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

State
Completed
Phase
Phase 3
People
22 taking part
Started
24 Oct 2017
Primary completion
12 Nov 2019
Arms
Onasemnogene Abeparvovec-xioi
Results
Posted on the registry
  1. 11 Oct 2017: Trial registered
  2. 24 Oct 2017: Trial started
  3. 12 Nov 2019: Trial completed
  4. 16 Jul 2020: Trial results posted

NCT03505099: Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2

State
Completed
Phase
Phase 3
People
30 taking part
Started
2 Apr 2018
Primary completion
15 Jun 2021
Arms
onasemnogene abeparvovec-xioi
Results
Posted on the registry
  1. 2 Apr 2018: Trial started
  2. 23 Apr 2018: Trial registered
  3. 15 Jun 2021: Trial completed
  4. 11 Jan 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Onasemnogene Abeparvovec-xioi, Zolgensma.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.